15 Oct
  • By Greg Freeman
  • Cause in

cTAP Publishes Comprehensive Analysis of the North Star Ambulatory Assessment (NSAA), a Newly Adopted Primary Outcome Measure in Clinical Trials of Patients with Duchenne Muscular Dystrophy

CAMBRIDGE, Mass.–(BUSINESS WIRE)–The collaborative Trajectory Analysis Project (cTAP), a multi-stakeholder, global coalition in Duchenne muscular dystrophy (DMD), publishes research in the journal PLOS ONE providing quantitative insights to assist the design and analysis of clinical trials in patients with DMD. The NSAA outcome measures the ability of patients to conduct a variety of activities – […]

READ MORE
27 Mar
  • By CureDuchenne User
  • Cause in

Catabasis Connection – March 2019

In the latest Catabasis Connection, they take us behind-the-scenes with the PolarisDMD experience. Learn what it’s like to participate in their PolarisDMD clinical trial. Read the full newsletter here.

READ MORE
14 Feb
  • By Jessica Yanez-Perez
  • Cause in

The Phase 3 PolarisDMD Trial Goes Global

With a flurry of recent activity, 17 trial sites are now open for enrollment. We are especially excited to share that our first international sites in Canada and Australia have launched. Sites are also expected to launch soon in Europe and Israel.

READ MORE
06 Feb
  • By CureDuchenne User
  • Cause in

NS Pharma Community Letter

We are excited that our industry partner, NS Pharma, has applied for accelertated approval for it’s exon 53 skipping therapy, viltolarsen. We applaud the dedication to the Duchenne community by NS Pharma and look forward to continued success. NS Pharma Community Letter

READ MORE